Samuel Dickson, PhD, Pentara Corporation, Millcreek, UT, discusses the concept of ‘time saved’ in disease progression for treatments in Alzheimer’s disease and how this is helping to shape the interpretation of disease modification. Expressing the efficacy of an investigative agent as time saved compared to placebo (i.e., months saved with treatment) has numerous putative benefits, including easier comparison between different outcomes and different trials, as well as being a more intuitive way for patients to understand clinical meaningfulness. This has been illustrated by Dr Dickson and colleagues in several recent anti-amyloid trials, including the recent TRAILBLAZER-ALZ study in which donanemab was shown to delay progression by around 5 months with 18-months of treatment. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2023 in Amsterdam, Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Sam Dickson is a Senior VP of Pentara Corporation, a company which consults with dozens of companies in the Alzheimer’s space, including Eisai, Biogen, Lilly, and Nutricia.